Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 7/20 | 0.49 |
| ▸ | CDK2 | P24941 | 7/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.49 |
| ▸ | CDK1 | P06493 | 6/20 | 0.49 |
| ▸ | CDK4 | P11802 | 6/20 | 0.49 |
| ▸ | CCND1 | P24385 | 6/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.49 |
| ▸ | CCND3 | P30281 | 6/20 | 0.49 |
| ▸ | CDK9 | P50750 | 6/20 | 0.49 |
| ▸ | CDK3 | Q00526 | 6/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284543 | 0.90 | STAT6 (0.51) | CCNA2CDK2CDK1CDK4CCND1 | |
| SCHEMBL1284193 | 0.86 | STAT6 (0.42) | CCNA2CDK2CDK1CDK4CCND1 | |
| SCHEMBL1285031 | 0.84 | STAT6 (0.42) | CCNA2CDK2CDK1CDK4CCND1 | |
| SCHEMBL1284623 | 0.84 | CDK4 (0.42) | CCNA2CDK2CCNT1CDK1CDK4 | |
| SCHEMBL1284834 | 0.83 | JAK3 (0.47) | JAK2BTK | |
| SCHEMBL1284577 | 0.83 | HDAC3 (0.47) | CCNA2CDK2CCNT1CDK4CCNE1 | |
| SCHEMBL1285329 | 0.83 | STAT6 (0.43) | CDK4CCND1CCND3STAT6BTK | |
| SCHEMBL1284285 | 0.83 | CDK4 (0.51) | CCNA2CDK2CDK1CDK4CCND1 | |
| SCHEMBL1284584 | 0.82 | SYK (0.45) | CCNA2CDK2CCNT1CDK1CDK4 | |
| SCHEMBL1284581 | 0.82 | TBK1 (0.54) | CCNA2CDK2CDK1CDK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | claimed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | claimed |
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2403853-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | Medical Research Council Technology (GB) | 2012-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088753-A1 | PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS | MARK3, MAPK8, CDK8 | CCNA2 609/4885CDK2 89/4885CCNT1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.